FindTrial
Sign In

Effects of melatonin in systemic lupus erythematosus

Effects of melatonin supplementation on clinical symptoms, disease activity and serum oxidative factors in patients with systemic lupus erythematosus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110708006975N6
Enrollment
50
Registered
2018-08-24
Start date
2018-09-23
Completion date
Unknown
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic lupus erythematosus. Systemic lupus erythematosus (SLE)

Interventions

Intervention 1: Intervention group: . Intervention 2: Control group: .

Sponsors

Connective Tissue Diseases Research Center, Tabriz Unversity of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having systemic lupus erythematosus according to ACR criteria and rheumatologist diagnosis Eager to participate in study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical symptoms. Timepoint: before and after intervention. Method of measurement: physician examination.;Disease activity. Timepoint: before and after intervention. Method of measurement: SLEDAI questionnaire.;Total antioxidant capacity. Timepoint: before and after intervention. Method of measurement: kit.;Malondialdehyde. Timepoint: before and after intervention. Method of measurement: florimetry.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Khabbazi

Connective Tissue Diseases Research center, Tabriz University of Medical Sciences

khabbazia@tbzmed.ac.ir+98 41 3336 9331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026